Fortress Biotech, Inc. Retained Earnings
Fortress Biotech, Inc. (FBIO) had Retained Earnings of -$624.15 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$624.15M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$623.68M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$734.05M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$730.12M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$624.15M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$623.68M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$734.05M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$730.12M 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$735.97M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$751.45M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$740.87M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$734.10M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$721.24M 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$710.29M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$694.87M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$685.59M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$680.55M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$655.77M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$634.23M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$607.09M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$584.58M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$563.22M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$547.46M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$515.90M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$495.12M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$491.58M 10-Q · filed 2021-05-17 |
| 2020-12-31 | -$482.76M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$477.46M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$461.92M 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$448.60M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$436.23M 10-K/A · filed 2021-04-09 |
| 2019-09-30 | -$420.74M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$407.98M 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$394.88M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$396.27M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$371.39M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$354.76M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$333.14M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$312.13M 10-K · filed 2019-03-18 |
| 2017-09-30 | -$301.71M 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$274.60M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$257.23M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$245.25M 10-K · filed 2018-03-16 |
| 2016-09-30 | -$227.82M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$214.84M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$202.36M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$190.16M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$178.12M 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$159.96M 10-Q · filed 2015-08-10 |
| 2015-03-31 | -$153.78M 10-Q · filed 2015-05-11 |
| 2014-12-31 | -$141.73M 10-K · filed 2016-03-15 |
| 2014-09-30 | -$138.01M 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$133.42M 10-Q · filed 2014-08-11 |
| 2014-03-31 | -$128.71M 10-Q · filed 2014-05-12 |
| 2013-12-31 | -$121.34M 10-K · filed 2015-03-16 |
| 2013-09-30 | -$111.54M 10-Q · filed 2013-11-01 |
| 2013-06-30 | -$103.71M 10-Q · filed 2013-08-05 |
| 2013-03-31 | -$93.04M 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$84.18M 10-K · filed 2014-03-14 |
| 2012-09-30 | -$75.52M 10-Q · filed 2012-11-14 |
| 2012-06-30 | -$69.58M 10-Q · filed 2012-08-08 |
| 2012-03-31 | -$63.13M 10-Q · filed 2012-05-15 |
| 2011-12-31 | -$56.57M 10-K · filed 2013-03-18 |
| 2011-09-30 | -$49.85M 10-Q · filed 2011-11-14 |
| 2010-12-31 | -$20.21M 10-K · filed 2012-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |